Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29699470 | 0.77 | POLA1 (0.47) | MAPTMEN1KMT2ARAPGEF4GRM4 | |
| SCHEMBL23457510 | 0.77 | MAPT (0.47) | MAPTMEN1KMT2ATP53 | |
| SCHEMBL29699617 | 0.76 | SCN9A (0.38) | MAPTEGFR | |
| SCHEMBL23457623 | 0.76 | SCN9A (0.38) | MAPTEGFR | |
| SCHEMBL29699563 | 0.73 | DHFR (0.41) | MAPTRAPGEF4GRM4 | |
| SCHEMBL29699530 | 0.72 | RAPGEF4 (0.42) | MEN1KMT2ARAPGEF4ALDH1A1EGFR | |
| SCHEMBL29699553 | 0.71 | PDGFRB (0.43) | MEN1KMT2AEGFRPDGFRB | |
| SCHEMBL23457521 | 0.71 | PDGFRB (0.43) | MEN1KMT2AEGFRPDGFRB | |
| SCHEMBL15831504 | 0.71 | MAPT (0.43) | MAPTMEN1KMT2ARAPGEF4ALDH1A1 | |
| SCHEMBL10577907 | 0.69 | ALDH1A1 (0.42) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | MAPT 1215/4885MEN1 2988/4885KMT2A 4011/4885 |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | MAPT 1082/4885MEN1 2927/4885KMT2A 3699/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | MAPT 1215/4885MEN1 2988/4885KMT2A 4011/4885 |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | MAPT 1215/4885MEN1 2988/4885KMT2A 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.